SpikePanel — See what the market is really discussing
$TXG10x Genomics, Inc. · Medical - Healthcare Information Services · $8.3B
Street Hold · PT $48.86 (-0.2%)
$65.12
+2.0%
Event thread
Key events, in time order
10 items
AnalystBull🔥Developing
TXG Hits 52-Week High, Featured in Strong Momentum Lists
Multiple sources confirm fresh 52-week high and strong momentum, extending post-guidance rally
D1 -0.3% · +5d -1.6%
›10 waves of this story
2026-07-22 At least three independent traders on social media cite TXG as a leader or healthcare long, providing multi-source confirmation
2026-07-23 TXG broke out to a 52-week high on July 21, up 9%, and is cited as a leader in the healthcare sector by traders.
2026-07-30 Zacks expects earnings beat, but trader warns against shorting short-term; mixed signals
2026-08-04 Today TXG appears on multiple traders' key market events and earnings week watchlists, and is noted as top weight in ARKG, extending pre-earnings attention.
2026-08-06 Q2 EPS loss of $0.14 beat $0.23 estimate; revenue topped; earnings call held
2026-08-09 Post-earnings momentum strong; multiple trader screens flag TXG as 52-week high or high-momentum name
2026-08-11 Guidance raise confirmed by multiple independent sources; stock hits 52-week high
2026-08-11 Multiple independent sources confirm new high and post-guidance gains, extending prior event line
2026-08-11 Multiple independent sources confirm sharp gains and new 52-week high, extending prior guidance-raise storyline
2026-08-22 Multiple sources confirm fresh 52-week high and strong momentum, extending post-guidance rally
2026-08-07 Q2 rev $151M incl Takara settlement; GM up
Earnings
Earnings report
D1 -3.9% · +5d +27.5%
8-K filing
8-K: Item 2.02, Item 9.01
D1 -3.9% · +5d +27.5%
Earnings
TXG Appears in Multi-Strategy Screener Amid Earnings Proximity
Multiple independent trader screeners list TXG, continuing the pre-earnings focus trend without new facts.
D1 -4.4% · +5d +10.1%
›2 waves of this story
2026-07-31 Multiple independent sources list TXG on Aug 3 week earnings & key events calendar, flagging upcoming results
2026-08-02 Multiple independent trader screeners list TXG, continuing the pre-earnings focus trend without new facts.
OtherBull
TXG repeatedly flagged as strong stock by multiple traders, top RS rank
Multiple independent trader accounts again listed TXG in strong stock scans on Jul 14-15, extending prior strength
D1 -0.9% · +5d +2.4%
›2 waves of this story
2026-07-10 TXG rose 15% to a 52-week high on Jul 9, and was listed on liquid leader scans by multiple independent trader accounts, indicating rising market attention.
2026-07-15 Multiple independent trader accounts again listed TXG in strong stock scans on Jul 14-15, extending prior strength
Earnings
10x Genomics to Report Q2 2026 Results on August 6
Official date set for Q2 earnings, market awaits results
D1 -0.1% · +5d +2.8%
Earnings
Earnings report
Q1 2026 revenue was $151 million, representing 9% growth over Q1 2025 excluding nonrecurring settlement revenue
D1 -1.4% · +5d -4.0%
8-K filing
8-K: Item 2.02, Item 9.01
D1 -1.4% · +5d -4.0%
①
Bull vs bear
by direction · sourced
Bull0
None yet
Bear0
None yet
Community
AI synthesis + sources
⑩
Discussion
be the first
Be civil · your views are your own
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
Event thread
Key events, in time order
10 items
AnalystBull🔥Developing
TXG Hits 52-Week High, Featured in Strong Momentum Lists
Multiple sources confirm fresh 52-week high and strong momentum, extending post-guidance rally
D1 -0.3% · +5d -1.6%
›10 waves of this story
2026-07-22 At least three independent traders on social media cite TXG as a leader or healthcare long, providing multi-source confirmation
2026-07-23 TXG broke out to a 52-week high on July 21, up 9%, and is cited as a leader in the healthcare sector by traders.
2026-07-30 Zacks expects earnings beat, but trader warns against shorting short-term; mixed signals
2026-08-04 Today TXG appears on multiple traders' key market events and earnings week watchlists, and is noted as top weight in ARKG, extending pre-earnings attention.
2026-08-06 Q2 EPS loss of $0.14 beat $0.23 estimate; revenue topped; earnings call held
2026-08-09 Post-earnings momentum strong; multiple trader screens flag TXG as 52-week high or high-momentum name
2026-08-11 Guidance raise confirmed by multiple independent sources; stock hits 52-week high
2026-08-11 Multiple independent sources confirm new high and post-guidance gains, extending prior event line
2026-08-11 Multiple independent sources confirm sharp gains and new 52-week high, extending prior guidance-raise storyline
2026-08-22 Multiple sources confirm fresh 52-week high and strong momentum, extending post-guidance rally
2026-08-07 Q2 rev $151M incl Takara settlement; GM up
Earnings
Earnings report
D1 -3.9% · +5d +27.5%
8-K filing
8-K: Item 2.02, Item 9.01
D1 -3.9% · +5d +27.5%
5 earlier events›
Earnings
TXG Appears in Multi-Strategy Screener Amid Earnings Proximity
Multiple independent trader screeners list TXG, continuing the pre-earnings focus trend without new facts.
D1 -4.4% · +5d +10.1%
›2 waves of this story
2026-07-31 Multiple independent sources list TXG on Aug 3 week earnings & key events calendar, flagging upcoming results
2026-08-02 Multiple independent trader screeners list TXG, continuing the pre-earnings focus trend without new facts.
OtherBull
TXG repeatedly flagged as strong stock by multiple traders, top RS rank
Multiple independent trader accounts again listed TXG in strong stock scans on Jul 14-15, extending prior strength
D1 -0.9% · +5d +2.4%
›2 waves of this story
2026-07-10 TXG rose 15% to a 52-week high on Jul 9, and was listed on liquid leader scans by multiple independent trader accounts, indicating rising market attention.
2026-07-15 Multiple independent trader accounts again listed TXG in strong stock scans on Jul 14-15, extending prior strength
Earnings
10x Genomics to Report Q2 2026 Results on August 6
Official date set for Q2 earnings, market awaits results
D1 -0.1% · +5d +2.8%
Earnings
Earnings report
Q1 2026 revenue was $151 million, representing 9% growth over Q1 2025 excluding nonrecurring settlement revenue
